Literature DB >> 6933502

Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.

D G Gilliland, Z Steplewski, R J Collier, K F Mitchell, T H Chang, H Koprowski.   

Abstract

We have constructed cell-specific cytotoxic agens by covalently coupling the A chain from diphtheria toxin or ricin toxin to monoclonal antibody directed against a colorectal carcinoma tumor-associated antigen. Antibody 1083-17-1A was modified by attachment of 3-(2-pyridyldithio)propionyl or cystaminyl groups and then treated with reduced A chain to give disulfide-linked conjugates that retained the original binding specificity of the antibody moiety. the conjugates showed cytotoxic activity for colorectal carcinoma cells in culture, but were not toxic in the same concentration range for a variety of cell lines that lacked the antigen. Under defined conditions virtually 100% of antigen-bearing cultured cells were killed, whereas cells that lacked the antigen were not affected. Conjugates containing toxin A chains coupled to monoclonal antibodies may be useful in studying functions of various cell surface components and, possibly, as tumor-specific therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6933502      PMCID: PMC349879          DOI: 10.1073/pnas.77.8.4539

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Diphtheria toxin: mode of action and structure.

Authors:  R J Collier
Journal:  Bacteriol Rev       Date:  1975-03

2.  The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies.

Authors:  R Levy; E Hurwitz; R Maron; R Arnon; M Sela
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

3.  The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.

Authors:  E Hurwitz; R Levy; R Maron; M Wilchek; R Arnon; M Sela
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

4.  Antibody as carrier of chlorambucil.

Authors:  T Ghose; S P Nigam
Journal:  Cancer       Date:  1972-05       Impact factor: 6.860

5.  Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target.

Authors:  F L Moolten; N J Capparell; S R Cooperband
Journal:  J Natl Cancer Inst       Date:  1972-10       Impact factor: 13.506

6.  The interaction of Ricinus communis agglutinin with normal and tumor cell surfaces.

Authors:  G L Nicolson; J Blaustein
Journal:  Biochim Biophys Acta       Date:  1972-05-09

7.  Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis.

Authors:  S Olsnes; A Pihl
Journal:  Biochemistry       Date:  1973-07-31       Impact factor: 3.162

8.  Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymically active and inactive fragments.

Authors:  R J Collier; J Kandel
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

9.  Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule.

Authors:  R Drazin; J Kandel; R J Collier
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

10.  Immunochemotherapy of cancer with chlorambucil-carrying antibody.

Authors:  T Ghose; S T Norvell; A Guclu; D Cameron; A Bodurtha; A S MacDonald
Journal:  Br Med J       Date:  1972-08-26
View more
  45 in total

Review 1.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

2.  A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity.

Authors:  W Z Wei; R J Massey; G H Heppner
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

4.  Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors:  A Eisenthal; S A Rosenberg
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

Review 5.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  National Pancreatic Cancer Project. Workshop on pancreatic tumor markers.

Authors:  H Z Kupchik; R A Reisfeld; V L Go
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

Review 7.  Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy.

Authors:  J Guy; D Drabek; M Antoniou
Journal:  Mol Biotechnol       Date:  1995-06       Impact factor: 2.695

8.  Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.

Authors:  K Imai; T Nakanishi; T Noguchi; A Yachi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.

Authors:  K Kishida; Y Masuho; M Saito; T Hara; H Fuji
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Transferrin-polycation conjugates as carriers for DNA uptake into cells.

Authors:  E Wagner; M Zenke; M Cotten; H Beug; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.